Abstract
Developing new drugs is slow and expensive, especially because the assessment of cardiac and hepatic toxicity in preclinical trials frequently leads to compound rejection. Toxicity assessment primarily requires animal models, which are physiologically distinct from humans. To enhance the accuracy of drug screening, cardiomyocytes and hepatocytes derived from human induced pluripotent stem…